CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
NCT Number: NCT01334645
The purpose of this study is to determine whether the combination of copeptine and troponin adds diagnosis information to that provided by troponin alone or the combination of troponin and myoglobin.
Hypothesis : If the values of troponin and copeptin are not elevated, diagnosis of acute myocardial infarction can be ruled out without prolonged monitoring and serial blood sampling.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Clermont-Ferrand, 63003, France
Patients older than 18 years with pain suggestive of Acute Coronary Syndrome, with onset within the last 12 hours, presenting to the Emergency Department of the University Hospital Gabriel Montpied (Clermont-Ferrand, France) and the General Hospital Henri Mondor (Aurillac, France) are enrolled.
Upon admission to the hospital, all patient underwent an initial clinical assessment, including medical history, temperature, respiratory rate, cardiac frequency, blood pressure, pulse oxymetry, 18-lead ECG, chest X-ray and screening blood test including C reactive protein, natremia, Troponine T, myoglobin, creatin kinase and copeptine.
Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.
Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.
Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.
The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.
Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.
Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.
The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected
Time frame: at day 1
Time frame: at 90 days
University Hospital, Clermont-Ferrand
Other
Diagnostic Value of Copeptin Assay for Acute Coronary Syndrome Without ST-segment Elevation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06404515
ASCVD, Acute Coronary Syndrome
New York, United States
View Trial DetailsNCT04125992
Acute Coronary Syndrome, Angina Pectoris
Nablus, Palestinian Territories
View Trial DetailsNCT05409716
Acute Coronary Syndrome, Angina Pectoris
Nablus, West Bank, Palestinian Territories
View Trial DetailsNCT00521976
Acute Coronary Syndrome, Angina Pectoris
Stavanger, Rogaland, Norway
View Trial Details